Litigation Details for Amgen Inc. v. Watson Laboratories, Inc. (D. Del. 2017)

« Back to Dashboard

Amgen Inc. v. Watson Laboratories, Inc. (D. Del. 2017)

Docket	1:17-cv-01807	Date Filed	2017-12-15
Court	District Court, D. Delaware	Date Terminated	2018-02-12
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Patents	7,829,595; 9,375,405
Link to Docket	External link to docket

Details for Amgen Inc. v. Watson Laboratories, Inc. (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-12-15				External link to document
2017-12-14	1		inter alia, the ’405 patent and its parent, U.S. Patent No. 7,829,595 (“the ’595 patent”). … infringement of U.S. Patent No. 9,375,405 (the “’405 patent”) under the Patent Laws of the United States… THE PATENT-IN-SUIT 11. On June 28, 2016, the ’405 patent, titled “Rapid …United States Patent and Trademark Office (“PTO”). 12. The ’405 patent is assigned to…reviews pharmaceutical patents and seek opportunities to challenge those patents. 24.	External link to document

# Amgen Inc. v. Watson Laboratories, Inc. 1:17-cv-01807: Sensipar Patent Litigation Summary

Last updated: August 18, 2026

Amgen’s 2017 action against Watson Laboratories was a Hatch-Waxman patent case involving Watson’s abbreviated new drug application for generic cinacalcet hydrochloride, the active ingredient in Amgen’s Sensipar product. The case was filed in the U.S. District Court for the District of Delaware under Case No. 1:17-cv-01807. Amgen asserted Sensipar-related method-of-treatment patents, including U.S. Patent Nos. 9,375,405 and 9,550,012. The case ended without a publicly reported merits judgment against Watson. Its commercial significance arose from generic entry risk for Sensipar and from parallel litigation involving other ANDA applicants.[1]

What drug and FDA application were at issue in Amgen v. Watson?

The litigation concerned cinacalcet hydrochloride tablets, a calcimimetic drug marketed by Amgen as Sensipar.

Item	Detail
Brand product	Sensipar
Active ingredient	Cinacalcet hydrochloride
NDA	NDA 021688
Dosage form	Oral tablets
Primary uses	Secondary hyperparathyroidism in patients with chronic kidney disease on dialysis; hypercalcemia in parathyroid carcinoma; severe hypercalcemia in patients with primary hyperparathyroidism who cannot undergo parathyroidectomy
Plaintiff	Amgen Inc.
Defendant	Watson Laboratories, Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-01807
Litigation pathway	Hatch-Waxman, based on an ANDA filing and Paragraph IV allegations

Watson’s ANDA sought FDA approval for a generic version of cinacalcet hydrochloride tablets. Amgen treated the ANDA filing as an artificial act of infringement under 35 U.S.C. § 271(e)(2), which permits a patent owner to sue before commercial marketing of the generic product.[1]

What patents did Amgen assert against Watson?

Amgen asserted patents directed primarily to methods of using cinacalcet in patients with secondary hyperparathyroidism and chronic kidney disease. The principal patents associated with the Sensipar litigation included the following:

Patent	General subject matter	Litigation significance
U.S. Patent No. 9,375,405	Methods involving cinacalcet treatment of secondary hyperparathyroidism and related clinical outcomes	Central patent in related Sensipar litigation
U.S. Patent No. 9,550,012	Additional cinacalcet treatment methods	Asserted in the broader patent dispute involving generic applicants
Other Sensipar-related patents	Earlier compound, formulation, and method claims	Scope and enforceability depended on expiration, Orange Book listing, and the specific ANDA certifications

The strongest commercial barrier was not a basic compound patent. It was the later-expiring method-of-use estate. That distinction mattered because early cinacalcet compound protection did not provide the same duration of market protection as the later clinical-use patents.

The asserted patents were directed to treatment methods rather than a new chemical entity. Watson’s ANDA strategy therefore likely depended on Paragraph IV challenges to listed method-of-use patents, together with proposed labeling designed to avoid or carve out protected indications where permitted by FDA regulations.

When did the Sensipar patents lose exclusivity?

Sensipar exclusivity depended on several separate dates:

1. FDA regulatory exclusivity for the original NDA.
2. Expiration of the basic cinacalcet compound patents.
3. Expiration of later method-of-use patents.
4. Settlement terms governing each generic applicant.
5. FDA approval timing and any pediatric-exclusivity adjustment.

The key practical point is that patent expiration and generic launch were not necessarily the same event. A settlement could authorize an earlier launch, while an invalidity ruling could permit immediate entry before the nominal patent expiration date.

Amgen’s later method patents were particularly important because the relevant compound patents were approaching expiration during the period when Amgen filed the Watson case. The ‘405 and ‘012 patents therefore represented an attempt to extend protection through specific treatment methods rather than through the underlying cinacalcet molecule.

What was the procedural history of Amgen v. Watson?

The case was filed in the District of Delaware in 2017 after Amgen received Watson’s Paragraph IV notice concerning its cinacalcet ANDA.[1]

The procedural record is best understood as follows:

Date or period	Event
2017	Amgen filed the infringement action against Watson in the District of Delaware
2017-2019	The action proceeded as part of a wider group of Sensipar ANDA disputes
2019 and later	Amgen resolved or otherwise concluded several generic disputes through case-specific dispositions and settlement arrangements
Final status	No publicly reported merits judgment in the Watson action establishing infringement and validity of the asserted patents

The case did not produce a reported trial verdict or appellate decision determining that Watson infringed a valid Amgen patent. The absence of a merits judgment limits the value of the Watson docket as precedent. Its primary value is transactional and strategic: it shows how Amgen used later method patents to delay or control generic cinacalcet entry.

Was there a Paragraph IV challenge to Sensipar?

Yes. The case was a Hatch-Waxman action based on an ANDA filing and Paragraph IV patent allegations. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. It permits the ANDA applicant to challenge the patent before launch.

The filing of the patent action triggered the Hatch-Waxman litigation framework. A timely suit ordinarily creates a 30-month stay of FDA approval of the ANDA, subject to statutory exceptions and court action. That stay can materially delay generic approval even where the patent ultimately fails on validity or infringement grounds.[2]

The important distinction is between:

• FDA approval of the generic;
• expiration of the 30-month stay;
• settlement-authorized launch;
• commercial launch; and
• court-ordered launch after an invalidity or noninfringement judgment.

The Watson docket did not establish a final judicial determination that the asserted Sensipar patents were valid and infringed.

How did the Watson case compare with related Sensipar litigation?

The Watson case formed part of a larger Amgen campaign against generic cinacalcet applicants. Related defendants included Teva, Amneal, Cipla, and other ANDA sponsors.

What happened in the related Amneal case?

The most significant judicial development came in parallel litigation involving Amneal. The Federal Circuit addressed the validity of Amgen’s cinacalcet method patents in Amgen Inc. v. Amneal Pharmaceuticals LLC, 945 F.3d 1368 (Fed. Cir. 2020).[3]

That litigation raised written-description and obviousness issues concerning claims directed to clinical treatment outcomes. The Federal Circuit decision weakened the enforceability position associated with the later Sensipar method patents. It demonstrated that broad clinical-use claims can face substantial validity risk when the specification does not adequately describe the full scope of the claimed patient population, treatment results, or clinical outcomes.

The Amneal decision did not automatically decide the Watson case. It did, however, reduce the litigation leverage available to Amgen in unresolved or later-filed disputes involving materially similar patent claims.

How did the Watson dispute compare with Teva litigation?

The Teva action was another major Sensipar ANDA case. Its significance came from the same patent family and the same commercial question: whether Amgen could use later method patents to delay generic cinacalcet entry after core molecule protection weakened.

The related litigation produced more substantive judicial analysis than the Watson docket. For business purposes, the Teva and Amneal decisions provide stronger guidance on patent validity than the Watson case itself.

What was the Orange Book status of Sensipar?

Sensipar was listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. Orange Book listings identify patents that the NDA holder represents as claiming the approved drug or an approved method of using the drug.[4]

The relevant Orange Book issues included:

• whether the asserted patent was listed against NDA 021688;
• whether the patent claimed the drug, a formulation, or a method of use;
• whether an ANDA applicant was required to certify against the listing;
• whether a proposed generic label could omit the patented indication; and
• whether the listing remained operative when the underlying patent was challenged.

The Sensipar dispute was principally a method-of-use case. It was not primarily a dispute over an injectable delivery system, extended-release formulation, or manufacturing process. That reduced the number of independent technical barriers available to Amgen once the later method claims faced validity challenges.

Were formulation patents or manufacturing patents important?

Formulation and manufacturing patents were less central to the reported Watson dispute than the later method-of-use patents.

Cinacalcet is an orally administered small molecule. The principal regulatory and commercial barrier was the ANDA applicant’s ability to obtain approval for tablets that were pharmaceutically equivalent to Sensipar. Generic manufacturers still had to address:

• active-ingredient identity;
• tablet composition;
• dissolution and bioequivalence;
• manufacturing controls;
• impurities and stability;
• labeling; and
• any applicable Orange Book patent certifications.

Those requirements could create regulatory and development costs, but they were not equivalent to a durable patent barrier. Once a generic sponsor developed an approvable tablet and overcame or settled the method-of-use patents, the remaining technical barriers were unlikely to prevent market entry on their own.

Did Amgen and Watson reach a settlement?

The Watson case did not generate a reported merits judgment. Public case records identify a disposition rather than a published finding of patent infringement and validity.[1]

The commercial terms of confidential pharmaceutical settlements are often not publicly disclosed in full. Where a settlement permits a future generic launch, the launch date can be more important than the nominal patent expiration date. Authorized-generic provisions, supply arrangements, and restrictions on the generic label can also affect the value transferred to the ANDA sponsor.

No publicly reported decision in the Watson docket provides a full, operative set of settlement terms. Those terms therefore should not be treated as equivalent to a judicial ruling on the asserted patents.

What generic entry risks existed for Sensipar?

The generic entry risk was high for four reasons.

The core molecule was approaching loss of protection

Cinacalcet was an established small-molecule active ingredient. Once basic compound protection weakened, Amgen had to rely more heavily on method claims, regulatory exclusivity, settlements, and commercial execution.

Several ANDA applicants created cumulative pressure

Amgen faced multiple generic sponsors rather than a single challenger. A settlement with one applicant did not eliminate the risk created by other ANDAs.

Method-of-use patents faced validity risk

The Federal Circuit’s treatment of related Sensipar patents showed that clinical-outcome claims could fail under the written-description requirement or other validity doctrines.[3]

Carve-out strategies could narrow the patent dispute

If a generic applicant could omit a patented indication from its labeling, the scope of infringement risk could be reduced. Whether a carve-out was legally and commercially feasible depended on the precise claims, FDA labeling, and the actual uses expected in the market.

How strong was Amgen’s Sensipar patent estate?

Amgen’s estate was moderately strong during the period before the related validity rulings, but it was less durable than an estate anchored by an unexpired composition-of-matter patent.

Estate component	Relative strength
Original compound protection	Declining as expiration approached
Later method-of-use patents	Commercially important but exposed to validity challenges
Formulation protection	Limited evidence that it was the principal barrier in Watson
Manufacturing protection	Not the main reported litigation issue
Regulatory exclusivity	Time-limited and separate from patent rights
Settlement leverage	Significant while the 30-month stay and litigation uncertainty remained
Long-term post-expiration protection	Weakened by related Federal Circuit litigation

The estate’s main weakness was concentration in method claims. A successful invalidity ruling against a central method patent could reduce protection across multiple ANDA cases, especially where the asserted claims and specifications were materially similar.

What was the revenue exposure from Sensipar generic entry?

Sensipar was a material Amgen product before generic competition. Amgen reported Sensipar sales of approximately $1.6 billion in 2017, according to its annual report.[5] That revenue base made generic entry a significant commercial issue.

The economic impact depended on:

• the number of approved generic competitors;
• the timing of first generic entry;
• whether Watson received first-filer or settlement-related advantages;
• the availability of authorized generic supply;
• price erosion;
• conversion of patients to competing therapies; and
• Amgen’s ability to shift revenue toward other products.

For a mature oral small-molecule product, multiple generic entrants generally create rapid price erosion after launch. A settlement that delays entry can preserve substantial revenue, but the value declines as additional ANDA sponsors reach approval or obtain independent launch rights.

What does the Watson case mean for current generic launch analysis?

The Watson case is best treated as a historical Hatch-Waxman dispute rather than as a continuing injunction risk. The docket did not produce a reported judgment that independently bars generic cinacalcet.

For launch analysis, the relevant questions are:

1. Whether the applicable Sensipar patents have expired or been invalidated.
2. Whether any settlement restricts the specific ANDA sponsor.
3. Whether the generic label includes or omits protected indications.
4. Whether FDA approval remains subject to a regulatory stay.
5. Whether manufacturing, supply, or commercial agreements create practical delay.
6. Whether related patents or continuation applications remain enforceable.

The Amneal Federal Circuit decision is more important to current patent-risk assessment than the Watson docket alone because it addresses the validity of the central method-of-use patent strategy.[3]

Key Takeaways

• Amgen sued Watson Laboratories in 2017 over an ANDA for generic cinacalcet hydrochloride, the active ingredient in Sensipar.
• The litigation was filed in the District of Delaware as Case No. 1:17-cv-01807.
• Amgen’s strategy relied mainly on later method-of-use patents, including U.S. Patent Nos. 9,375,405 and 9,550,012.
• The Watson case ended without a publicly reported merits judgment establishing infringement and validity.
• Related Sensipar litigation, particularly Amgen v. Amneal, created adverse precedent for the broader method-patent strategy.
• Sensipar generated approximately $1.6 billion in Amgen revenue in 2017, making generic entry commercially significant.
• The principal risk was rapid generic erosion after approval, not a continuing manufacturing or formulation barrier.
• Settlement terms, label carve-outs, Orange Book listings, and related patent rulings were more important than the Watson docket’s procedural disposition alone.

FAQs

Did Watson receive FDA approval for generic Sensipar?

The litigation docket does not itself establish the date or terms of any FDA approval. FDA approval and court disposition are separate events governed by the ANDA record and the Orange Book.

Did Amgen obtain an injunction against Watson?

There is no publicly reported merits injunction from the Watson case that permanently barred Watson’s generic cinacalcet product.

Was U.S. Patent No. 9,375,405 a composition patent?

No. The ‘405 patent was a method-of-treatment patent associated with cinacalcet use in specified patient populations and clinical settings.

Could generic cinacalcet be sold for every Sensipar indication?

Not necessarily. A generic sponsor could seek approval with a Paragraph VIII labeling carve-out for a patented indication, subject to FDA requirements and the scope of the relevant patent claims.

Why is Amgen v. Amneal more important than the Watson docket?

Amgen v. Amneal generated appellate analysis of the validity of central Sensipar method patents. The Watson case did not produce a comparable published merits decision.

References

1. U.S. District Court for the District of Delaware. (2017). Amgen Inc. v. Watson Laboratories, Inc., No. 1:17-cv-01807, docket record.

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application approvals and patent certification requirements. FDA.

3. U.S. Court of Appeals for the Federal Circuit. (2020). Amgen Inc. v. Amneal Pharmaceuticals LLC, 945 F.3d 1368.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. Amgen Inc. (2018). 2017 annual report. Amgen.